The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I study of oral live biotherapeutic MRx0518 with hypofractionated preoperative radiation for resectable pancreatic cancer.
 
Cullen M. Taniguchi
Consulting or Advisory Role - Phebra; Xerient
Patents, Royalties, Other Intellectual Property - Oral amifostine for radio protection of the intestinal tract; PHD inhibitors for radio protection of the GI Tract
 
Sonal S Noticewala
No Relationships to Disclose
 
Cara L. Haymaker
Stock and Other Ownership Interests - Briacell
Consulting or Advisory Role - Nanobiotix
Research Funding - BTG (Inst); Dragonfly Therapeutics (Inst); Idera (Inst); Iovance Biotherapeutics (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Patent Appl No. 62/977, 672 (Inst)
 
Prajnan Das
Honoraria - Bayer; Imedex; Physicans' Education Resource
 
Ethan B. Ludmir
Employment - Alaunos Therapeutics (I)
 
Anirban Maitra
Consulting or Advisory Role - Freenome; Tezcat Biosciences
Patents, Royalties, Other Intellectual Property - Johns Hopkins University has licensed a patent related to pancreatic cancer to Thrive Earlier Detection. I have 1.8% contribution on that patent. No royalties have been received by me.; PCT/US2017/066851 (Inst)
 
Shubham Pant
Consulting or Advisory Role - AskGene Pharma; Boehringer Ingelheim; Ipsen; Janssen; Novartis; Zymeworks
Research Funding - 4D Pharma (Inst); Amal Therapeutics (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); bionte (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Elicio Therapeutics (Inst); Immuneering (Inst); ImmunoMET (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); Mirati Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Purple Biotech (Inst); Rgenix (Inst); Xencor (Inst); Zymeworks (Inst)